AbbVie

News

Cerevel Parkinson’s data adds lustre to AbbVie acquisition

Cerevel Therapeutics’ Parkinson’s disease therapy tavapadon has shown efficacy in a phase 3 trial, reinforcing its blockbuster potential and no doubt delighting AbbVie, wh

News

After ph3 win, Roche eyes earlier use of Columvi in DLBCL

Roche’s CD20xCD3 bispecific antibody Columvi has improved survival when used as a second-line therapy for diffuse large B-cell lymphoma (DLBCL) in a phase 3 trial, setting

News

NICE backs AbbVie’s oral therapy for migraine prevention

AbbVie’s Aquipta has become the first once-daily oral therapy for both chronic and episodic migraine prevention to be recommended by NICE for NHS patients in England and W

News

AbbVie inks $713m deal for OSE chronic inflammation drug

AbbVie has made another bolt-on deal in the immunology and inflammation category, paying $48 million upfront for rights to an antibody in preclinical development at OSE Im

News

Regeneron set for August FDA decision on BCMA bispecific

Regeneron’s bid to join the market for BCMA-targeted bispecific antibodies for multiple myeloma is nearing a conclusion, with the FDA starting a priority review of its lin

News

AbbVie looks internally for its new CEO, naming COO Michael

The speculation over who will replace long-serving AbbVie chief executive Richard Gonzalez is over, as the company confirms that president and chief operating officer Robe

Cerevel Parkinson’s data adds lustre to AbbVie acquisition

After ph3 win, Roche eyes earlier use of Columvi in DLBCL

NICE backs AbbVie’s oral therapy for migraine prevention

AbbVie inks $713m deal for OSE chronic inflammation drug

Regeneron set for August FDA decision on BCMA bispecific

AbbVie looks internally for its new CEO, naming COO Michael

Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer

Discover a new era of healthcare panel engagement: Grounded ...

AbbVie

Editor's Picks